Virtual populations.
Real decisions.

Specialists in modelling non-communicable diseases

Tackling population health challenges means asking big questions, such as:

What impact will the increasing burden of chronic kidney disease have on healthcare costs over the next 20 years?
How can you look 10 to 20 years ahead to understand the impact of a new drug on its users and your revenue stream?
How do you determine whether it is clinically and financially feasible to progress a drug from Phase II to Phase III clinical trials?
What would be the health and economic benefits of earlier screening for the diagnosis and treatment of conditions such as chronic kidney disease or liver disease?
How can you boost a nation’s health with targeted help at different life stages?

And how do you even know which are the right questions to ask?

That’s where we can help.

Helping you make the best decisions

Our simulation and analysis expertise turns tomorrow’s population health questions and challenges into today’s focussed, specific, actionable decisions.

We can help you understand and explore those questions and challenges far into the future. Our scenario modelling will show you how different kinds of health interventions, drug innovations and policy changes can impact them.

And that will help you choose the best way forward.

Why Us?

Deep expertise in modelling non-communicable diseases, combined with entrepreneurial vision.

Why Us?

How do we do it?

We’ve created a specific process to help you find, ask and answer the right questions.

Method

What have we done?

We’ve answered many different kinds of questions for many different organisations in over 70 countries.

Track Record

Why choose us?

We have an experienced and multi-disciplinary team of software engineers, population health and policy research experts, and mathematicians.

Team

HealthLumen Blog

Reducing Failure Rates of Phase 3 Clinical Trials: how microsimulation modelling can assist

Of the three main phases of clinical trials, by far the most expensive part of the process is the Phase 3 trial, typically requiring from several hundred to several thousand participants and costing up to $20 million on average. Furthermore, the process is fraught with risks with up to 70% of Phase 2 trials and […]

Read

Liver disease: unravelling the interacting risk factors

Obesity is increasing across Europe and, together with alcohol consumption, is contributing to rising rates of chronic liver diseases, and related conditions [1,2,3]; alcoholic liver disease will shortly overtake ischaemic heart disease in the number of years of working life lost (3). Quantifying the epidemiological and economic burden of obesity and alcohol-related conditions is essential […]

Read

NEWS: Making Conversations Count for All – Benefits of improving delivery of smoking cessation interventions for different socioeconomic groups

Today, Cancer Research UK has published a new report ‘Making Conversations Count for All: Benefits of improving delivery of smoking cessation interventions for different socioeconomic groups’ which includes modelling conducted by HealthLumen. This builds on the previous 2020 report, which aimed to estimate the burden of active smoking related disease in the UK and quantify the health and economic […]

Read

The future burden of chronic kidney disease (CKD): how we have climbed “INSIDE CKD” with AstraZeneca using microsimulation-based computer modelling to help improve health outcomes

HealthLumen, in conjunction with AstraZeneca, have recently published a body of research from the “INSIDE CKD” programme, part of a major strategic initiative at AstraZeneca which is dedicated to changing the future for CKD patients. Our role is to support evidence-based policy making in CKD, which we do by harnessing the predictive power of microsimulation, […]

Read